Comera Life Sciences Holdings, Inc. (CMRA)
USD 0.0
(-50.0%)
USD 0.0
(-50.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2022 | 328.44 Thousand USD | 105.31% |
| 2021 | -6.18 Million USD | -119981.5% |
| 2020 | 5161.00 USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q2 | 330.38 Thousand USD | 126.07% |
| 2023 Q1 | -1.26 Million USD | -485.91% |
| 2023 Q3 | -1.59 Million USD | -583.15% |
| 2022 Q3 | -1.39 Million USD | 69.25% |
| 2022 Q2 | -4.52 Million USD | -26.78% |
| 2022 Q1 | -3.56 Million USD | 42.31% |
| 2022 FY | 328.44 Thousand USD | 105.31% |
| 2022 Q4 | 328.44 Thousand USD | 123.61% |
| 2021 Q1 | 155.42 Thousand USD | 0.0% |
| 2021 FY | -6.18 Million USD | -119981.5% |
| 2021 Q4 | -6.18 Million USD | -1273.2% |
| 2021 Q3 | -450.55 Thousand USD | 0.0% |
| 2020 FY | 5161.00 USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| America Great Health | 1.81 Million USD | 81.915% |
| Ampio Pharmaceuticals, Inc. | -3.81 Million USD | 108.609% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | 73.809% |
| Biora Therapeutics, Inc. | 32.21 Million USD | 98.98% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | 134.978% |
| Better Therapeutics, Inc. | -860 Thousand USD | 138.191% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 101.381% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | 92.813% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | 105.64% |
| Evelo Biosciences, Inc. | 3.19 Million USD | 89.73% |
| Evolutionary Genomics, Inc. | 3.16 Million USD | 89.628% |
| Finch Therapeutics Group, Inc. | 5 Million USD | 93.434% |
| Galera Therapeutics, Inc. | 134.04 Million USD | 99.755% |
| Innovation1 Biotech Inc. | 179.15 Thousand USD | -83.333% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | 97.338% |
| Molecular Templates, Inc. | 707 Thousand USD | 53.544% |
| Navidea Biopharmaceuticals, Inc. | 438.44 Thousand USD | 25.089% |
| NexImmune, Inc. | -3.13 Million USD | 110.481% |
| Orgenesis Inc. | 21.78 Million USD | 98.492% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | 87.445% |
| Point of Care Nano-Technology, Inc. | -498.00 USD | 66052.008% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | 106.972% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | 363.649% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | 99.704% |
| Statera Biopharma, Inc. | 14.41 Million USD | 97.722% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | 104.324% |
| Trevena, Inc. | 2.25 Million USD | 85.454% |
| Vaxxinity, Inc. | 10.13 Million USD | 96.758% |
| Vaccinex, Inc. | -1.28 Million USD | 125.5% |
| Vicapsys Life Sciences, Inc. | 344.44 Thousand USD | 4.647% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | 97.519% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | -356.409% |